J Underwood1, D De Francesco2, F A Post3, J H Vera4, I Williams5, M Boffito6, P W Mallon7, J Anderson8, M Sachikonye9, C Sabin2, A Winston1. 1. Division of Infectious Diseases, Imperial College London, London, UK. 2. Research Department of Infection & Population Health, University College London - Royal Free Campus, London, UK. 3. Kings College Hospital NHS Foundation Trust, London, UK. 4. Brighton and Sussex University Hospitals NHS Foundation Trust & Brighton and Sussex Medical School, Brighton, UK. 5. University College London, London, UK. 6. Chelsea and Westminster Healthcare NHS Foundation Trust, London, UK. 7. School Of Medicine, University College Dublin, Dublin, Ireland. 8. Homerton University Hospital, London, UK. 9. UK Community Advisory Board, London, UK.
Abstract
OBJECTIVES: While cognitive impairment is frequently reported in HIV-positive individuals and has historically been associated with poorer functional outcomes, the associations between cognitive impairment and patient-reported outcome measures (PROMs) in contemporary cohorts are unclear. METHODS: We tested cognitive function using a computerized battery (CogState™ ) in 290 HIV-positive and 97 HIV-negative individuals aged ≥ 50 years participating in the Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study. Participants completed questionnaires detailing physical and mental health [Short Form Health Survey (SF-36)], cognitive function [European AIDS Clinical Society (EACS) questions], activities of daily living [Lawton Instrumental Activities of Daily Living (IADL)], depression [Patient Depression Questionnaire (PHQ-9) and Centres for Epidemiologic Studies Depression scale (CES-D)], falls and sexual desire. Cognitive impairment was defined using the Frascati criteria, global deficit score (GDS) and multivariate normative comparison (MNC). In the HIV-positive group, the classification performances of the different definitions of cognitive impairment and dichotomized questionnaire results were calculated. RESULTS: The prevalence of cognitive impairment in the HIV-positive group was 34.5% (GDS), 30.0% (Frascati) and 22.1% (MNC), with only 2% diagnosed with HIV-associated dementia. In general, the associations between cognitive impairment and PROMs were weak regardless of the definition used: mean c-statistics were 0.543 (GDS), 0.530 (MNC) and 0.519 (Frascati). Associations were similar using the global T-score to define cognitive impairment. Summary health scores (SF-36) were lower, but only significantly so for those with cognitive impairment identified using MNC, for both mental health (61.4 vs. 75.8; P = 0.03) and physical health (60.9 vs. 75.0; P = 0.03). CONCLUSIONS: The associations between cognitive impairment and PROMs were weak, possibly because impairment was mild and therefore largely asymptomatic. Further work is needed to elucidate the clinical implications of cognitive impairment in HIV-disease.
OBJECTIVES: While cognitive impairment is frequently reported in HIV-positive individuals and has historically been associated with poorer functional outcomes, the associations between cognitive impairment and patient-reported outcome measures (PROMs) in contemporary cohorts are unclear. METHODS: We tested cognitive function using a computerized battery (CogState™ ) in 290 HIV-positive and 97 HIV-negative individuals aged ≥ 50 years participating in the Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study. Participants completed questionnaires detailing physical and mental health [Short Form Health Survey (SF-36)], cognitive function [European AIDS Clinical Society (EACS) questions], activities of daily living [Lawton Instrumental Activities of Daily Living (IADL)], depression [Patient Depression Questionnaire (PHQ-9) and Centres for Epidemiologic Studies Depression scale (CES-D)], falls and sexual desire. Cognitive impairment was defined using the Frascati criteria, global deficit score (GDS) and multivariate normative comparison (MNC). In the HIV-positive group, the classification performances of the different definitions of cognitive impairment and dichotomized questionnaire results were calculated. RESULTS: The prevalence of cognitive impairment in the HIV-positive group was 34.5% (GDS), 30.0% (Frascati) and 22.1% (MNC), with only 2% diagnosed with HIV-associated dementia. In general, the associations between cognitive impairment and PROMs were weak regardless of the definition used: mean c-statistics were 0.543 (GDS), 0.530 (MNC) and 0.519 (Frascati). Associations were similar using the global T-score to define cognitive impairment. Summary health scores (SF-36) were lower, but only significantly so for those with cognitive impairment identified using MNC, for both mental health (61.4 vs. 75.8; P = 0.03) and physical health (60.9 vs. 75.0; P = 0.03). CONCLUSIONS: The associations between cognitive impairment and PROMs were weak, possibly because impairment was mild and therefore largely asymptomatic. Further work is needed to elucidate the clinical implications of cognitive impairment in HIV-disease.
Authors: Adolf Pfefferbaum; Natalie M Zahr; Stephanie A Sassoon; Dongjin Kwon; Kilian M Pohl; Edith V Sullivan Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2018-07-04
Authors: G Guaraldi; A Malagoli; A Calcagno; C Mussi; B M Celesia; F Carli; S Piconi; G V De Socio; A M Cattelan; G Orofino; A Riva; E Focà; S Nozza; G Di Perri Journal: BMC Geriatr Date: 2018-04-20 Impact factor: 3.921
Authors: Jonathan Underwood; Davide De Francesco; James H Cole; Matthan W A Caan; Rosan A van Zoest; Ben A Schmand; David J Sharp; Caroline A Sabin; Peter Reiss; Alan Winston Journal: Open Forum Infect Dis Date: 2019-05-03 Impact factor: 3.835
Authors: José Damas; Bruno Ledergerber; Isaure Nadin; Philip E Tarr; Marcel Stoeckle; Ursi Kunze; Christoph Hauser; Klemens Gutbrod; Alexandra Calmy; Frédéric Assal; Patrick Schmid; Thomas Hundsberger; Caroline Di Benedetto; Stefania Rossi; Barbara Hasse; Ladina Schlosser; Renaud Du Pasquier; Katharine E A Darling; Matthias Cavassini Journal: AIDS Date: 2021-12-01 Impact factor: 4.177
Authors: Kate Alford; Stephanie Daley; Sube Banerjee; Elizabeth Hamlyn; Daniel Trotman; Jaime H Vera Journal: Qual Life Res Date: 2022-05-17 Impact factor: 3.440
Authors: M Metral; I Nadin; I Locatelli; P E Tarr; A Calmy; H Kovari; P Brugger; A Cusini; K Gutbrod; P Schmid; M Schwind; U Kunze; C Di Benedetto; R Pignatti; R Du Pasquier; Kea Darling; M Cavassini Journal: HIV Med Date: 2019-12-27 Impact factor: 3.180